Malaga Cove Capital LLC Sells 644 Shares of DexCom, Inc. (NASDAQ:DXCM)

Malaga Cove Capital LLC trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 16.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,331 shares of the medical device company’s stock after selling 644 shares during the quarter. Malaga Cove Capital LLC’s holdings in DexCom were worth $259,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of DXCM. Czech National Bank grew its holdings in DexCom by 3.7% in the fourth quarter. Czech National Bank now owns 84,689 shares of the medical device company’s stock worth $6,586,000 after purchasing an additional 3,057 shares during the period. Capital Investment Advisors LLC acquired a new stake in DexCom in the fourth quarter worth $206,000. 180 Wealth Advisors LLC acquired a new stake in DexCom in the fourth quarter worth $255,000. Allen Mooney & Barnes Investment Advisors LLC acquired a new stake in DexCom in the fourth quarter worth $477,000. Finally, Park Avenue Securities LLC grew its holdings in DexCom by 13.9% in the fourth quarter. Park Avenue Securities LLC now owns 13,347 shares of the medical device company’s stock worth $1,038,000 after purchasing an additional 1,627 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DXCM. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Barclays lifted their price objective on shares of DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a report on Monday, May 5th. Piper Sandler cut their price target on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.11.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company’s stock, valued at $10,002,636.06. This represents a 4.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. The trade was a 8.03% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,926 shares of company stock valued at $4,734,384. Company insiders own 0.32% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $86.52 on Thursday. The company’s 50 day moving average is $71.40 and its 200-day moving average is $77.41. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $132.26. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market cap of $33.93 billion, a P/E ratio of 60.50, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the firm earned $0.32 EPS. Sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.